Nesyrgy (Amlodipine Besilate, Nebivolol Hydrochloride)

Amlodipine besilate and nebivolol hydrochloride, the active ingredients in Nesyrgy, are a calcium‑channel blocker and a beta‑blocker respectively, presented as an oral tablet for oral use. They are used to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Nesyrgy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nesyrgy combines a calcium‑channel blocker and a beta‑blocker to manage hypertension.

- Primary hypertension: lowers systolic and diastolic blood pressure in adults with essential hypertension. - Secondary hypertension: contributes to blood‑pressure control when an underlying cause has been identified and treated. - Hypertension requiring combination therapy: provides additive blood‑pressure reduction for patients who need more than one agent to achieve target levels.

Adverse reactions may occur with any antihypertensive therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness, especially after standing. - Fatigue: general feeling of tiredness. - Flushing: transient warmth and redness of the skin. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Bradycardia: abnormally slow heart rate. - Hepatic dysfunction: elevated liver enzymes. - Allergic reactions: rash, itching, or swelling of face/lips. - Heart failure exacerbation: worsening shortness of breath. - Angio‑edema: rapid swelling of lips, tongue, or throat.

Patients should be evaluated for cardiovascular and hepatic status before initiating therapy.

- Assess baseline blood pressure: ensure appropriate starting level. - Review cardiac history: avoid in uncontrolled heart failure. - Monitor liver function: periodic tests recommended. - Caution in elderly: start at lower dose to reduce orthostatic effects. - Avoid abrupt discontinuation: taper under medical supervision. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Drug‑interaction potential should be reviewed before prescribing.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels. - Non‑dihydropyridine calcium‑channel blockers (e.g., verapamil, diltiazem): additive negative inotropic effect. - Other beta‑blockers: risk of excessive bradycardia and hypotension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance hypotensive effect. - Antihyperglycemics: may mask hypoglycaemia symptoms. - NSAIDs: can reduce antihypertensive efficacy. - Lithium: may increase lithium concentrations. - Alcohol: can potentiate dizziness and hypotension.